FAM174B Inhibitors
FAM174B Inhibitors are a class of chemical compounds specifically designed to downregulate the activity of the protein FAM174B. The inhibition of FAM174B is a complex process that involves the interaction of these inhibitors with various signaling pathways that FAM174B is known to influence or participate in. Each inhibitor in this category interacts with FAM174B or its associated pathways in a unique manner, leading to the suppression of the protein's functionality. The design of these inhibitors takes into account the biochemical environment surrounding FAM174B, including the substrates, cofactors, and interacting proteins that are part of its activity spectrum. By binding to FAM174B itself or by altering the surrounding biological milieu, these inhibitors ensure a decrease in the functional activity of the protein. This can be achieved through direct binding to the active site of FAM174B, altering its conformation and rendering it inactive, or by interfering with upstream signaling molecules that regulate FAM174B activity, effectively decreasing its functional output.
The specificity of FAM174B Inhibitors is key to their function, as they are designed to target particular motifs or domains within the protein structure, which are crucial for its activity. Some inhibitors may mimic substrate molecules, competitively binding to the active site and preventing the proper substrate from interacting with FAM174B. Others might bind to allosteric sites, inducing a conformational change that affects the protein's activity. Additionally, certain inhibitors work by disrupting the interaction between FAM174B and other regulatory proteins, impeding signaling cascades that would normally lead to FAM174B activation. The complexity of these interactions underscores the sophisticated nature of FAM174B Inhibitors, which are the result of intricate chemical engineering to achieve selective and potent inhibition of FAM174B function, thereby reducing its involvement in specific cellular pathways without affecting the broader cellular processes.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is a potent inhibitor of phosphoinositide 3-kinases (PI3K). By inhibiting PI3K, it can prevent the phosphorylation and subsequent activation of AKT, which is involved in numerous cellular processes including survival, proliferation, and growth. As FAM174B's function could be regulated by AKT signaling, Wortmannin indirectly leads to the functional inhibition of FAM174B by impeding AKT-mediated pathways. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is another PI3K inhibitor, similar in function to Wortmannin. By blocking PI3K activity, LY294002 disrupts AKT signaling, potentially reducing the activity of downstream proteins such as FAM174B that are regulated via this pathway. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin is an mTOR inhibitor that can downregulate protein synthesis and cell proliferation pathways that may involve FAM174B. By inhibiting mTOR, Rapamycin can indirectly reduce the functional activity of FAM174B by limiting the cellular processes in which it may be involved. | ||||||
Triciribine | 35943-35-2 | sc-200661 sc-200661A | 1 mg 5 mg | $102.00 $138.00 | 14 | |
Triciribine specifically inhibits the activation of AKT without affecting other kinases. This specific blockade could decrease the functional activity of FAM174B if it is downstream of or dependent on AKT-mediated signaling for its activity. | ||||||
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $315.00 | ||
Palbociclib is a selective inhibitor of cyclin-dependent kinases CDK4 and CDK6. If FAM174B activity is linked to the cell cycle progression controlled by these kinases, its inhibition could indirectly reduce FAM174B activity by disrupting the cell cycle. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 is a MEK inhibitor that interferes with the MAPK/ERK pathway. If FAM174B is regulated by the MAPK/ERK signaling, inhibition by PD98059 could indirectly decrease FAM174B activity by altering the pathway's output. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is a specific inhibitor of p38 MAPK. Inhibition of p38 MAPK could lead to decreased functional activity of FAM174B if it is part of or influenced by the p38 MAPK signaling cascade. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $65.00 $267.00 | 257 | |
SP600125 is an inhibitor of JNK, which plays a role in apoptosis and cell differentiation. If FAM174B activity is modulated by JNK signaling, inhibition by SP600125 could result in reduced FAM174B function. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $182.00 $693.00 | 88 | |
Y-27632 is a selective inhibitor of ROCK kinases. By inhibiting ROCK, it may affect cytoskeletal organization and related signaling pathways that could indirectly influence FAM174B activity. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 selectively inhibits MEK1 and MEK2, which are upstream of ERK in the MAPK pathway. If FAM174B is regulated by ERK signaling, U0126 could indirectly reduce FAM174B activity through this pathway. | ||||||